Protagonist Therapeutics Inc

18. Sept. 2026, 20:06 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

17. Sept. 2026, 19:46 UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

16. Sept. 2026, 19:13 UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

15. Sept. 2026, 20:07 UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

11. Sept. 2026, 20:08 UTC

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

9. Sept. 2026, 20:07 UTC

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2. Sept. 2026, 20:08 UTC

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

1. Sept. 2026, 19:36 UTC

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

28. Aug. 2026, 20:02 UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

27. Aug. 2026, 20:07 UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

26. Aug. 2026, 20:08 UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

25. Aug. 2026, 23:36 UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

24. Aug. 2026, 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

21. Aug. 2026, 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

20. Aug. 2026, 19:31 UTC

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

19. Aug. 2026, 19:46 UTC

Protagonist Therapeutics Inc shares are lower today, retracing from earlier highs. The price remains above its 20-day moving average amid no specific news.

17. Aug. 2026, 19:46 UTC

BMO Capital raised Protagonist Therapeutics' price target to $178, maintaining an Outperform rating, as shares trade higher amid positive pipeline developments.

14. Aug. 2026, 22:36 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

13. Aug. 2026, 20:06 UTC

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

12. Aug. 2026, 23:31 UTC

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

11. Aug. 2026, 23:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

10. Aug. 2026, 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

6. Aug. 2026, 19:52 UTC

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5. Aug. 2026, 22:02 UTC

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4. Aug. 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3. Aug. 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31. Juli 2026, 19:36 UTC

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30. Juli 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29. Juli 2026, 19:43 UTC

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28. Juli 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.